Table 4.
Characteristics of patients in groups classified by the achievement of at least 30% parathyroid hormone reduction form baseline after 12 weeks of cinacalcet treatment (n = 135).
| Parametersa | Parathyroid hormone reduction from baseline | p valueb | |
|---|---|---|---|
| At least 30% reduction (n = 79) | Less than 30% reduction (n = 56) | ||
| CASR genotypes | 0.019 | ||
| G carriers, n (%) | 66 (64.1) | 37 (35.9) | |
| G noncarriers, n (%) | 13 (40.6) | 19 (59.4) | |
| bPTH (*100 pg/mL) | 1277.0 (1025.0, 1629.0) | 1189.5 (983.3, 1688.6) | 0.646 |
| bPhos (mg/dL) | 4.4 ± 1.3 | 5.0 ± 1.5 | 0.013 |
| bCa (mg/dL) | 9.6 (9.2, 10.1) | 10.0 ± 0.8 | 0.016 |
| bCtriol (μg/week) | 2.0 (1.5, 3.0) | 1.0 (0.8, 1.8) | 0.001 |
| bErgo (*20,000 IU/month) | 8.0 (4.0, 12.0) | 4.0 (4.0, 8.0) | 0.206 |
| AGE (years) | 62.4 ± 12.8 | 55.3 ± 12.7 | 0.002 |
AGE age on the day of starting cinacalcet, bCa baseline serum calcium concentration, bCtriol baseline calcitriol dose or relative calcitriol equivalent dose of alfacalcidol, bErgo ergocalciferol dose before starting cinacalcet, bPhos baseline serum phosphate concentration, bPTH baseline serum intact parathyroid hormone concentration.
aContinuous data are expressed with either means ± standard deviations if they are normally distributed or medians (interquartile ranges) if they are not normally distributed.
bThe p values were calculated with the use of the chi-square test, the Mann–Whitney U test, or the t-test for comparison between G carriers and noncarriers.